(Q26801002)

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Are surrogate markers adequate to assess cardiovascular disease drugs?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic Acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Remnant cholesterol as a causal risk factor for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Monocytes in coronary artery disease and atherosclerosis: where are we now?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

How do statins work?: changing paradigms with implications for statin allocation

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

The remnants of residual risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Ratio of eicosapentaenoic acid to arachidonic acid is a critical risk factor for acute coronary syndrome in middle-aged older patients as well as younger adult patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic acid induces neovasculogenesis in human endothelial progenitor cells by modulating c-kit protein and PI3-K/Akt/eNOS signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Effects of fatty acids on endothelial cells: inflammation and monocyte adhesion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Atherosclerosis. the road ahead

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Triglycerides and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

n-3 fatty acids and cardiovascular events after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

n-3 fatty acids in patients with multiple cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Distribution, interconversion, and dose response of n-3 fatty acids in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Triglycerides on the rise: should we swap seats on the seesaw?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Reactive oxygen species and endothelial function--role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

A philosophical analysis of the Hill criteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic Acid supplementation changes Fatty Acid composition and corrects endothelial dysfunction in hyperlipidemic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Plasma lipoproteins enhance tissue factor-independent factor VII activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Coronary Plaque Disruption

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Monocyte and macrophage dynamics during atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Ezetimibe: rescued by randomization (clinical and mendelian)

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Residual macrovascular risk in 2013: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Omega-3 fatty acid supplementation and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

The role of nitric oxide on endothelial function

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic acid protects against palmitic acid-induced endothelial dysfunction via activation of the AMPK/eNOS pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Eicosapentaenoic Acid Prevents Saturated Fatty Acid-Induced Vascular Endothelial Dysfunction: Involvement of Long-Chain Acyl-CoA Synthetase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Relationships between plasma fatty acid composition and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2015.07.035

7 January 2021